# ASCERTAIN: Assessment of Everolimus in Addition to Calcineurin Inhibitor Reduction in the Maintenance of Renal Transplant Recipients

> **NCT00170846** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 394 (actual)

## Conditions studied

- Renal Transplantation

## Interventions

- **DRUG:** Everolimus (RAD001)
- **DRUG:** Calcineurin Inhibitors (CNI)
- **DRUG:** Mycophenolate acid (MPA)/Azathioprine (AZA)
- **DRUG:** Steroids

## Key facts

- **NCT ID:** NCT00170846
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 394 (ACTUAL)
- **Last updated:** 2015-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00170846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00170846, "ASCERTAIN: Assessment of Everolimus in Addition to Calcineurin Inhibitor Reduction in the Maintenance of Renal Transplant Recipients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00170846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*